Helix BioPharma, a clinical-stage biopharmaceutical company, commits to innovating with purpose in this challenging landscape ...

An executive order signed on Tuesday, May 15, necessitated a change in plans for this panel discussion from the 2025 ...

May 1, 2025Kura Oncology, Inc. misses on earnings expectations. Reported EPS is $-0.66 EPS, expectations were $-0.51.

A new drug application seeking the approval of ziftomenib was submitted to the FDA on April 8, 2025. This indication is for ...

Community Oncology Conference, Nini Wu, MD, Navista, shares how AI can transform community oncology. The evolving role of ...

Fintel reports that on May 2, 2025, JP Morgan initiated coverage of CG Oncology (NasdaqGS:CGON) with a Overweight ...

Thanks to budget cuts, many potential insights and treatments needed to propel oncology forward will never be realized.

Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and part of JSR Life Sciences and Japan-based JSR Corporation, is pleased to announce the extension ...

The Oncology Institute, Inc.’s TOI share price has surged by 10.89%, which has investors questioning if this is right time to ...

In this video interview, C.K. Wang, MD, chief medical officer, COTA, discusses how real-world data and real-world evidence ...

Citius Oncology, Inc.’s CTOR share price has dipped by 6.04%, which has investors questioning if this is right time to buy.

In an information-overloaded environment, how can we make sure that the right cancer treatment finds the right patient?